zeltia sa (ZLIXF) Key Developments
Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015
Dec 15 14
Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.
Zeltia Reports Earnings Results for the Nine Months Ended September 2014
Oct 30 14
Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.
Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014
Sep 29 14
Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014 . Venue: Palais Brongni, 28 Place de la Bourse, entrée Rue Vivienne, 75002 Paris, France.
Zeltia Announces Earnings Results for the Second Quarter and First Half Ended June 30, 2014
Jul 29 14
Zeltia announced earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported that loss attributable to equity-holders of the parent was €147,000, compared to a loss attributable to equity-holders of the parent of €1.41 million for the same quarter ended June 30, 2013. Total revenue was €44.92 million, compared to €41.03 million for the same quarter ended June 30, 2013.
For the first half, the company reported net sales amounted to €78.2 million up 10% with respect to the same period last year. EBITDA amounted to €22.1 million in first half of 2014, a 12% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for €24 million against €22.5 million in first half of 2013. EBITDA increased notably despite the increase in R&D spending +9.8%, attributable mainly to the pivotal Phase III trial with Aplidin in multiple myeloma. Income attributable to equity-holders of the parent was €16.75 million, compared to €14.40 million for the same period ended June 30, 2013. Total revenue was €98.05 million, compared to €91.19 million for the same period ended June 30, 2013.
Zeltia SA to Report Q2, 2014 Results on Jul 29, 2014
Jul 21 14
Zeltia SA announced that they will report Q2, 2014 results on Jul 29, 2014